Researchers from UGA develop nasal vaccine for COVID

A nasal vaccine for COVID 19, developed by researchers from the University of Georgia, is on its way to clinic trials. The drug was concocted by the UGA startup Cyan Vac LLC.

From Brandon Ward, UGA Media Relations…

University of Georgia-based startup CyanVac LLC received federal funding to support a comparative Phase 2b clinical trial of CVXGA, the company’s intranasal vaccine candidates designed to protect against COVID-19.

As part of the award from Project NextGen, a federal initiative based in the U.S. Department of Health and Human Services (HHS), CyanVac will sponsor a randomized, double-blind Phase 2b study with 10,000 participants to compare the efficacy and safety of the intranasal vaccine against an FDA-approved mRNA-based COVID-19 vaccine.

The new vaccine is based on a viral delivery platform developed by He containing modified strains of parainfluenza virus 5, which causes kennel cough in dogs but is harmless to humans.

CyanVac was founded by Biao He, Regents’ Entrepreneur, Fred C. Davison Distinguished University Chair in Veterinary Medicine and a faculty member in UGA’s College of Veterinary Medicine (CVM). He served on a White House panel to advise on the future of COVID-19 vaccines and was named both UGA Inventor and Entrepreneur of the Year.

“We are very excited about this opportunity to test a novel intranasal COVID vaccine whose technology platform has been developed at UGA,” said He, who is based in UGA’s Department of Infectious Diseases. “The name of our vaccine—CVXGA—is a tribute to UGA and CVM whose support over the years made this possible.”

Project NextGen’s goal is to advance new, innovative vaccines and therapeutics that provide longer lasting and more durable protection against COVID-19. The award is one of the first made through the Rapid Response Partnership Vehicle, a consortium funded by the HHS Biomedical Advanced Research and Development Authority (BARDA) to accelerate product and technology development.

The Phase 2b study, which will begin this fall, will be carried out by BARDA’s Clinical Studies Network, focusing on evaluating the vaccine in a subset of participants who are at a higher risk of severe disease.

©2024 Cox Media Group